Facets (new session)
Description
Metadata
Settings
owl:sameAs
Inference Rule:
b3s
b3sifp
dbprdf-label
facets
http://dbpedia.org/resource/inference/rules/dbpedia#
http://dbpedia.org/resource/inference/rules/opencyc#
http://dbpedia.org/resource/inference/rules/umbel#
http://dbpedia.org/resource/inference/rules/yago#
http://dbpedia.org/schema/property_rules#
http://www.ontologyportal.org/inference/rules/SUMO#
http://www.ontologyportal.org/inference/rules/WordNet#
http://www.w3.org/2002/07/owl#
ldp
oplweb
skos-trans
virtrdf-label
None
About:
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
schema:ScholarlyArticle
, within Data Space :
wasabi.inria.fr
associated with source
document(s)
Type:
Academic Article
research paper
schema:ScholarlyArticle
New Facet based on Instances of this Class
Attributes
Values
type
Academic Article
research paper
schema:ScholarlyArticle
isDefinedBy
Covid-on-the-Web dataset
has title
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity
Creator
Dubé, Mathieu
Nussenzweig, Michel
Baxter, Amy
Butler, Allison
Caskey, Marina
Cohen, Yehuda
Gruell, Henning
Jankovic, Mila
Kaufmann, Daniel
Klein, Florian
Lu, Ching-Lan
Mendoza, Pilar
Niessl, Julia
Shimeliovich, Irina
Source
PMC
abstract
Combination antiretroviral therapy (ART) is highly effective in controlling human immunodeficiency virus (HIV)-1 but requires lifelong medication due to the existence of a latent viral reservoir(1,2). Potent broadly neutralizing antibodies (bNAbs) represent a potential alternative or adjuvant to ART. In addition to suppressing viremia, bNAbs may have T cell immunomodulatory effects as seen for other forms of immunotherapy(3). However, this has not been established in individuals who are infected with HIV-1. Here, we document increased HIV-1 Gag-specific CD8(+) T cell responses in the peripheral blood of all nine study participants who were infected with HIV-1 with suppressed blood viremia, while receiving bNAb therapy during ART interruption(4). Increased CD4(+) T cell responses were detected in eight individuals. The increased T cell responses were due both to newly detectable reactivity to HIV-1 Gag epitopes and the expansion of pre-existing measurable responses. These data demonstrate that bNAb therapy during ART interruption is associated with enhanced HIV-1-specific T cell responses. Whether these augmented T cell responses can contribute to bNAb-mediated viral control remains to be determined.
has issue date
2020-02-03
(
xsd:dateTime
)
bibo:doi
10.1038/s41591-019-0747-1
bibo:pmid
32015556
has license
no-cc
sha1sum (hex)
2393e84cbe8d570d83b5adb14dcfd8654e933329
schema:url
https://doi.org/10.1038/s41591-019-0747-1
resource representing a document's title
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity
has PubMed Central identifier
PMC7018622
has PubMed identifier
32015556
schema:publication
Nat Med
resource representing a document's body
covid:2393e84cbe8d570d83b5adb14dcfd8654e933329#body_text
is
schema:about
of
named entity 'Publisher'
named entity 'Combination'
named entity 'viruses'
named entity 'HIV-1'
named entity 'anti-HIV'
named entity 'IFN-γ'
named entity 'orders of magnitude'
named entity 'antisense'
named entity 'viremia'
named entity 'gp41'
named entity 'clinical complications'
named entity 'CD4 +'
named entity 'CD4 +'
named entity 'vaccination'
named entity 'clinical trials'
named entity 'PBS'
named entity 'PD-L1'
named entity 'primer'
named entity 'human leukocyte antigen'
named entity 'RPMI'
named entity 'MIP'
named entity 'plasma'
named entity 'Nature MediciNe'
named entity 'gp41'
named entity 'IFN-γ'
named entity 'autologous'
named entity 'CD8 +'
named entity 'hydrophobic'
named entity 'GraphPad Prism'
named entity 'CD4 +'
named entity 'GitHub'
named entity 'confidence intervals'
named entity 'HIV-1'
named entity 'DMSO'
named entity 'epitopes'
named entity 'HIV-1'
named entity 'HIV-1'
named entity 'long-term'
named entity 'viral load'
named entity 'protein'
named entity 'PBS'
named entity 'AIDS'
named entity 'CD4 +'
named entity 'CD4 +'
named entity 'Env'
named entity 'Bio-Rad Laboratories'
named entity 'IFN-γ'
named entity 'gp41'
named entity 'HIV-1'
named entity 'dye'
named entity 'penicillin'
named entity 'HIV-1'
named entity 'surface markers'
named entity 'Maximum likelihood'
named entity 'gp41'
named entity 'orders of magnitude'
named entity 'BSA'
named entity 'ATI'
named entity 'regression coefficient'
named entity 'TNF-α'
named entity 'IFN-γ'
named entity 'peptides'
named entity 'HIV-1'
named entity 'RNA'
named entity 'ClustalW'
named entity 'ELISpot'
named entity 'immunodominant'
named entity 'epitopes'
◂◂ First
◂ Prev
Next ▸
Last ▸▸
Page 1 of 6
Go
Faceted Search & Find service v1.13.91 as of Mar 24 2020
Alternative Linked Data Documents:
Sponger
|
ODE
Content Formats:
RDF
ODATA
Microdata
About
OpenLink Virtuoso
version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software